ATE253354T1 - Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen - Google Patents
Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungenInfo
- Publication number
- ATE253354T1 ATE253354T1 AT00905431T AT00905431T ATE253354T1 AT E253354 T1 ATE253354 T1 AT E253354T1 AT 00905431 T AT00905431 T AT 00905431T AT 00905431 T AT00905431 T AT 00905431T AT E253354 T1 ATE253354 T1 AT E253354T1
- Authority
- AT
- Austria
- Prior art keywords
- pseudoephedrine
- pellets
- pharmaceutically acceptable
- loratadine
- release
- Prior art date
Links
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 title abstract 4
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 title abstract 4
- 229960003908 pseudoephedrine Drugs 0.000 title abstract 4
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003088 loratadine Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 title 1
- 239000008188 pellet Substances 0.000 abstract 7
- 150000003839 salts Chemical class 0.000 abstract 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000002981 blocking agent Substances 0.000 abstract 1
- 239000007963 capsule composition Substances 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- -1 fatty acid ester Chemical class 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000000454 talc Substances 0.000 abstract 1
- 229910052623 talc Inorganic materials 0.000 abstract 1
- 235000012222 talc Nutrition 0.000 abstract 1
- 229920003176 water-insoluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR19990005873 | 1999-02-23 | ||
| PCT/KR2000/000130 WO2000050015A1 (en) | 1999-02-23 | 2000-02-18 | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE253354T1 true ATE253354T1 (de) | 2003-11-15 |
Family
ID=19574799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00905431T ATE253354T1 (de) | 1999-02-23 | 2000-02-18 | Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6251427B1 (de) |
| EP (1) | EP1154762B1 (de) |
| JP (1) | JP3645816B2 (de) |
| CN (1) | CN1161112C (de) |
| AT (1) | ATE253354T1 (de) |
| AU (1) | AU2697100A (de) |
| DE (1) | DE60006362T2 (de) |
| ES (1) | ES2204517T3 (de) |
| HK (1) | HK1043945B (de) |
| WO (1) | WO2000050015A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506783B1 (en) * | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
| US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
| EP1214072A2 (de) * | 1999-09-21 | 2002-06-19 | Schering Corporation | Verwendung von desloratadine zur behandlung von entzündlicher und allergischer zustände |
| WO2003000264A1 (en) * | 2001-06-20 | 2003-01-03 | Schering Corporation | Antihistamines for the treatment of nasal congestion and nasal obstruction |
| FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
| MXPA04009968A (es) | 2002-04-09 | 2004-12-13 | Flamel Tech Sa | Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s). |
| US20040033257A1 (en) * | 2002-05-30 | 2004-02-19 | Strides Inc. | Pharmaceutical formulation in a drug delivery system and process for preparing the same |
| PE20050202A1 (es) * | 2003-05-12 | 2005-05-14 | Dasan Medichen Co Ltd | La composicion farmaceutica de liberacion controlada de pseudoefredina o sus sales |
| EP1660047B1 (de) | 2003-08-13 | 2013-11-27 | Biocon Limited | Mikroteilchenförmige fettsäure-salz-festdosis-formulierungen für therapeutische mittel |
| ATE419841T1 (de) * | 2003-09-03 | 2009-01-15 | Pharmaton Sa | Kapseln enthaltend wirkstoffpellets mit unterschiedlichen freisetzungsprofilen |
| US20070190125A1 (en) | 2004-03-03 | 2007-08-16 | Constantine Georgiades | Positioning feature for aiding use of film or strip product |
| CA2653950A1 (en) * | 2006-06-01 | 2007-12-13 | Schering Corporation | Phenylephrine pulsed release formulations and pharmaceutical compositions |
| CN104161736A (zh) | 2006-06-01 | 2014-11-26 | Msd消费保健品公司 | 包含去氧肾上腺素的缓释药物制剂 |
| WO2008005287A1 (en) * | 2006-06-30 | 2008-01-10 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant |
| JP5668317B2 (ja) * | 2009-04-24 | 2015-02-12 | 大正製薬株式会社 | プソイドエフェドリン含有製剤粒子 |
| US20110218209A1 (en) * | 2010-03-06 | 2011-09-08 | Paul Daniel Yered | Nutrient delievry drug composition |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2738303A (en) * | 1952-07-18 | 1956-03-13 | Smith Kline French Lab | Sympathomimetic preparation |
| US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US5314697A (en) * | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
| KR960006917A (ko) | 1994-08-13 | 1996-03-22 | 김태훈 | 테르페나딘과-염산슈도에페드린 복합 펠렛(pellet) 조성물 |
| EP0941091A1 (de) * | 1996-10-31 | 1999-09-15 | Schering Corporation | Loratadin und dekongestirum enthaltende zusammensetzung zur behandlung von asthma |
| US5840329A (en) * | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
-
2000
- 2000-02-18 AT AT00905431T patent/ATE253354T1/de not_active IP Right Cessation
- 2000-02-18 JP JP2000600627A patent/JP3645816B2/ja not_active Expired - Fee Related
- 2000-02-18 ES ES00905431T patent/ES2204517T3/es not_active Expired - Lifetime
- 2000-02-18 AU AU26971/00A patent/AU2697100A/en not_active Abandoned
- 2000-02-18 EP EP00905431A patent/EP1154762B1/de not_active Expired - Lifetime
- 2000-02-18 HK HK02105460.8A patent/HK1043945B/zh not_active IP Right Cessation
- 2000-02-18 DE DE60006362T patent/DE60006362T2/de not_active Expired - Fee Related
- 2000-02-18 CN CNB008041857A patent/CN1161112C/zh not_active Expired - Fee Related
- 2000-02-18 WO PCT/KR2000/000130 patent/WO2000050015A1/en not_active Ceased
- 2000-02-22 US US09/507,995 patent/US6251427B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60006362T2 (de) | 2004-08-26 |
| AU2697100A (en) | 2000-09-14 |
| HK1043945B (zh) | 2005-02-08 |
| WO2000050015A1 (en) | 2000-08-31 |
| JP2002537323A (ja) | 2002-11-05 |
| HK1043945A1 (en) | 2002-10-04 |
| US6251427B1 (en) | 2001-06-26 |
| DE60006362D1 (de) | 2003-12-11 |
| CN1341014A (zh) | 2002-03-20 |
| EP1154762A1 (de) | 2001-11-21 |
| ES2204517T3 (es) | 2004-05-01 |
| JP3645816B2 (ja) | 2005-05-11 |
| EP1154762B1 (de) | 2003-11-05 |
| CN1161112C (zh) | 2004-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60006362D1 (de) | Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen | |
| DK0797435T3 (da) | Matrice til kontrolleret frigivelse af lægemidler | |
| IL111647A (en) | Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation | |
| CA2264238A1 (fr) | Forme galenique a liberation prolongee de milnacipran | |
| UA88056C2 (uk) | Дозована форма оксикодону, що вводиться один раз на день | |
| DK0923934T3 (da) | Modified release-matrixformulering af cefaclor og cephalexin | |
| BR9609663A (pt) | Formulações para desprendimento controlado de medicamentos fracamente soluveis | |
| CA2346001A1 (en) | Controlled release nanoparticulate compositions | |
| DE69331906D1 (de) | Granulierte pharmazeutische zusammensetzung | |
| ES512393A0 (es) | "un procedimiento para preparar una composicion farmaceutica de liberacion mantenida a base de indoramin micronizado". | |
| EP2036558A3 (de) | Oral anzuwendende opioidhaltige Zusammensetzungen mit verlängerter Wirkung | |
| JPH04501425A (ja) | ロラタジン、イブプロフェンおよびプソイドエフェドリンを含む薬剤組成物 | |
| WO2004108162A3 (en) | Controlled release pharmaceutical composition | |
| ATE424810T1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
| AU1351788A (en) | Slow-release pharmaceutical agent | |
| CZ225596A3 (en) | Film-coated tablets of paracetamol and domperidon | |
| CA2389236A1 (en) | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach | |
| CA2383212A1 (en) | Controlled release oral dosage suitable for oral administration | |
| DE60035579D1 (de) | Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme | |
| JP2004522780A5 (de) | ||
| WO2006011001A3 (en) | Controlled release compositions of divalproex sodium | |
| RU96123569A (ru) | Лекарственный препарат | |
| RU98111607A (ru) | Фармацевтические готовые формы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |